الفهرس 
Expression of pdl1 in early stage invasive breast carcinoma and its relation to tumor microenvironment
AbstractOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
Although breast carcinoma had many targeted biomarkers
for its treatment, it is a heterogenous disease with different outcomes and
needs new markers. Programmed death-ligand 1 (PDL1) is a new target with
unclear role. The aim of this study was to examine the prevalence of PDL1
in early-stage invasive breast carcinoma and to elucidate its relation to tumor
infiltrating lymphocytes (cytotoxic T-cells and regulatory T-cells), breast
carcinoma subtypes, established clinicopathological factors, disease-free
survival and overall survival.
Material and Methods: One hundred and nine cases of early-stage
invasive breast carcinoma were evaluated for age, grade, tumor size, stage
and node status. Also, they were retrieved immunohistochemically for
estrogen receptor, progesterone receptor, Her2/neu and Ki-67 then classified
into five molecular subtypes. PDL1, FOXP3 and CD8 immunostaining were
done and analyzed for all studied cases. PDL1 expression was correlated
with two types of tumor infiltrating lymphocytes (CD8+ cytotoxic T-cells
and FOXP3+ regulatory T-cells), histopathological factors, breast cancer
subtypes, disease-free survival and overall survival.
Results: PDL1 was expressed in 11% of the studied cases. It was
significantly associated with high grade tumors and FOXP3+ regulatory T cells while it revealed reverse relation to CD8+ cytotoxic T-cells. It was also
expressed in a reasonable number of triple negative breast carcinoma
(16.1%) with no significant relation to different molecular subtypes. PDL1